Vivacit-E Post-market Follow-up Study

Who can take part

• Patient is 18 to 60 years of age, inclusive
• Patient is skeletally mature
• Patient qualifies for primary unilateral or bilateral total hip arthroplasty (THA) based on physical exam and medical history including at least one of the following:
• Osteoarthritis
• Avascular necrosis (AVN)
• Post-traumatic arthritis
• Congenital hip dysplasia
• Patient has no history of previous total hip replacement or arthrodesis of the affected hip joint(s)
• Patient is willing and able to provide written informed consent
• Patient is willing and able to cooperate in the required post-operative therapy
• Patient is willing and able to complete scheduled follow-up evaluations as described in the Informed Consent
• Patient has participated in the Informed Consent process and has signed the IRB/EC approved informed consent

Who cannot take part

• The patient is:; a prisoner mentally incompetent or unable to understand what participation in the study entails a known alcohol or drug abuser; anticipated to be non-compliant; The patient has an acute, chronic, or systemic infection(s); The patient has total or partial absence of the muscular or ligamentous apparatus; The patient has neuromuscular compromise, vascular deficiency or other conditions in the affected limb that may lead to inadequate skeletal fixation; The patient has osteoradionecrosis; The patient has lack of bony structures proximal or distal to the operative joint, so that good implant fixation is unlikely or impossible; The patient has local bone tumors/cysts in the bone to be retained that the implanting surgeon determines could inhibit implant fixation; The patient is skeletally immature; The patient has any concomitant disease that can jeopardize the functioning and the success of the implant; The patient is known to be pregnant; The patient has a known sensitivity or allergic reaction to one or more of the implanted materials which include metal (titanium, tivanium, tantalum, cobalt, chromium, nickel) and ceramic
• Patient is unwilling or unable to give consent or to comply with the follow-up program
• Patient has a total prosthetic hip replacement device (including surface replacement arthroplasty, endoprosthesis, etc. in the affected hip joint(s)
• Inflammatory Arthritis
• Rheumatoid Arthritis